[back to articles & presentations]
[page 1][references]

Articles and Presentations

Are Various Babesia Species a Missed Cause for Hypereosinophilia?
A Follow-up on the First Reported Case of Imatinib Mesylate for Idiopathic Hypereosinophilia

By James L. Schaller, MD, MAR; Glenn A. Burkland, DMD; PJ Langhoff
Medscape General Medicine. 2007;9(1):38. ©2007 Medscape
Posted 02/27/2007

References

  1. Schaller JL, Burkland GA. Rapid and complete control of idiopathic hypereosinophilia with imatinib mesylate. Medscape General Medicine. 2001;3(3). Available at: http://www.medscape.com/viewarticle/408170 Accessed February 9, 2007
  2. Schaller JL. The Health Care Professional's Guide to the Treatment and Diagnosis of Human Babesiosis, An Extensive Review of New Human Species and Advanced Treatments. Tampa, Fla: Hope Academic Press; 2006:43-49
  3. Conrad PA, Kjemtrup AM, Carreno RA, et al. Description of Babesia duncani n.sp. (Apicomplexa: Babesiidae) from humans and its differentiation from other piroplasms. Int J Parasitol. 2006;36:779-789. Epub 2006 May 4.
  4. Gutierrez Y. Blood apicomplexa: plasmodium, Babesia and entopolypoides. In: Diagnostic Pathology of Parasitic Infections With Clinical Correlations. Philadelphia, Pa: Lea Febiger; 1990;9:146.
  5. Leeflang P, Oomen JMV, Zwart D, et al. The prevalence of Babesia antibodies in Nigerians. Int J Parasitol. 1976;6:156-161.
  6. Osorno BM, Vega C, Ristic M, et al. Isolation of Babesia spp. from asymptomatic human beings. Vet Parasitol. 1976;2:111-120.
  7. Gleich GJ, Leiferman KM, Pardanani A, Tefferi A, Butterfield JH. Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet. 2002;359:1577-1578.
  8. Anghel G, De Rosa L, Ruscio C, et al. Efficacy of imatinib mesylate in a patient with idiopathic hypereosinophilic syndrome and severe heart involvement. Tumori. 2005;91:67-70
  9. Ault P, Cortes J, Koller C, Kaled ES, Kantarjian H. Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate. Leuk Res. 2002;26:881-884.
  10. Salem Z, Zalloua PA, Chehal A, et al. Effective treatment of hypereosinophilic syndrome with imatinib mesylate. Hematol J. 2003;4:410-412.
  11. Musto P, Falcone A, Sanpaolo G, et al. Heterogeneity of response to imatinib-mesylate (glivec) in patients with hypereosinophilic syndrome: implications for dosing and pathogenesis. Leuk Lymphoma. 2004;45:1219-1222
  12. Cortes J, Ault P, Koller C, et al. Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome. Blood. 2003;101:4714-4716. Epub 2003 Feb 20.
  13. Tan D, Hwang W, Ng HJ, Goh YT, Tan P. Successful treatment of idiopathic hypereosinophilic syndrome with imatinib mesylate: a case report. Int J Hematol. 2004;80:75-77
  14. Wilkins HJ, Crane MM, Copeland K, Williams WV. Hypereosinophilic syndrome: an update. Am J Hematol. 2005;80:148-157.
  15. Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003;348:1201-1214.
  16. Imashuku S, Kakazu N, Ueda I, et al. Response to imatinib mesylate in a patient with idiopathic hypereosinophilic syndrome associated with cyclic eosinophil oscillations. Int J Hematol. 2005;81:310-314.
  17. Quick RE, Herwaldt BL, Thomford JW, et al. Babesiosis in Washington State: a new species of Babesia? Ann Intern Med. 1993;119:284-290.
  18. Lin AJ, Ager AL Jr, Klayman DL. Antimalarial activity of dihydroartemisinin derivatives by transdermal application. Am J Trop Med Hyg. 1994;50:777-783.
  19. Klayman D, Ager LA Jr, Fleckenstein L, Lin AJ. Transdermal artelinic acid: an effective treatment for Plasmodium berghei-infected mice. Am J Trop Med Hyg. 1991;45:602-607.
  20. Zhao KC, Xuan WY, Zhao Y, Song ZY. The pharmacokinetics of a transdermal preparation of artesunate in mice and rabbits. Yao Xue Xue Bao. 1989;34:813-816.
  21. Thriemer K, Wernsdorfer G, Rojanawatsirivet C, Kollaritsch H, Sirichainsinthop J, Wernsdorfer WH. In vitro activity of artemisinin alone and in combination with retinol against Plasmodium falciparum. Wien Klin Wochenschr. 2005;117(suppl 4):45-48.
  22. LaValle JA, Krinsky DL, Hawkin EB, Pelton R, Willis A. Natural Therapeutics Pocket Guide 2000-2001. Hudson, Ohio: Lexi-Comp; 518, 531.
  23. World Health Organization. The use of artemisinin and its derivatives as anti-malarial drugs. WHO/MAL/98.1086. Malaria Unit, Division of Control of Tropical Diseases. Geneva: WHO; 1998.
  24. WHO and UNICEF. Global Financing, Commodities and Service Delivery. World Malaria Report 2005. Available at: http://rbm.who.int/wmr2005/html/3-1.htm Accessed February 9, 2007.
  25. Schaller JL. Artemisin, Artesunate, Artemisinic Acid and Other Derivatives of Artemisia Used for Malaria, Babesia and Cancer: A Health Care Practitioner's Guide to Dosage, Side Effects, Effectiveness, Toxicity and Interations. A Review of the Research on the Most Common Clinical Artemisia Medications. Tampa, Fla: Hope Academic Press; 2006:134-138.
  26. Schaller JL. Suboxone. Tampa, Fla: Hope Academic Press; 2006:11-14, 33-35.
  27. Orinda GO, Waltisbuhl DJ, Young AS, Wright IG. Low doses of natural human interferon alpha inhibit the development of Babesia microti infection in BALB/c mice. Vet Parasitol. 1994;53:53-58.
  28. Igarashi I, Suzuki R, Waki S, et al. Roles of CD4(+) T cells and gamma interferon in protective immunity against Babesia microti infection in mice. Infect Immun. 1999;67:4143-4148.
  29. Schaller JL. The Health Care Professional's Guide to the Treatment and Diagnosis of Human Babesiosis: An Extensive Review of New Human Species and Advanced Treatments. Tampa, Fla: Hope Academic Press; 2006:105-106.
  30. Yoon TY, Ahn GB, Chang SH. Complete remission of hypereosinophilic syndrome after interferon-alpha therapy: report of a case and literature review. J Dermatol. 2000;27:110-115.
  31. Ahmed JS. The role of cytokines in immunity and immunopathogenesis of pirolasmoses. Parasitol Res. 2002;88(13 suppl 1):S48-S50.
  32. Munter S, Way M, Frischknecht F. Signaling during pathogen infection. Sci STKE. 2006;2006(335):re5.
  33. Ray A, Quade J, Carson CA, Ray BK. Calcium-dependent protein phosphorylation in Babesia bovis and its role in growth regulation. J Parasitol. 1990;76:153-161.
  34. Tefferi A. Modern diagnosis and treatment of primary eosinophilia. Acta Haematol. 2005;114:52-60.
  35. Rothschild BM. Hypereosinophilic syndrome. eMedicine from WebMD. 2005 Jan 31. Available at: http://www.emedicine.com/ped/topic1069.htm Accessed January 2, 2007.
  36. Butterfield JH. Interferon treatment for hypereosinophilic syndromes and systemic mastocytosis. Acta Haematol. 2005;114:26-40.
  37. Henderson SO, Magana RN. Babesiosis. eMedicine from WebMD. 2006 Mar 8. Available at: http://www.emedicine.com/emerg/topic49.htm Accessed January 2, 2007.
[top of page][page 1][references]
[back to articles & presentations]